linjc16/ctgov huggingface dataset:
The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to test the sensitivity and specificity of a shunt tap to predict shunt failure.

Official Title
-----------------
The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction

Conditions
-----------------
Signs or Symptoms of Shunt Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient has clinically suspected shunt malfunction. The patient has had an imaging study of the head. The patient needs a shunt revision. Exclusion Criteria: The patient has not had an imaging study of the head.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Quality of Life of Patients With Pregnancy Related VTE

Study Overview
=================
Brief Summary
-----------------
A retrospective study of the quality of life and problems experienced by patients who developed pregnancy related VTE. It involves patients seen at JUH in 2012-2020. A questionnaire will be filled by those patients and any other patients in Jordan. It was translated to an Arabic form from EQ-5D, VEINES-QOL/SYM questionnaire and PEmb-QoL. The quality of their lives will be assessed and the problems encountered are going to be analyzed to try to find some solutions. This project is going to be a national research project with the efforts to try to find common platforms for those patients and nidus to establish a national support group.

Detailed Description
-----------------
Retrospective study and analysis using a questionnaire which will be distributed to patients. The patients' data and contact details (phone numbers, whatsApp, email address…) will be collected from their clinical records at the JUH hospital. The period 2012-2020 will be covered. The questionnaire link is; file:///C:/Users/user/Downloads/QoL-post-VTE-during-pregnancy-5.pdf and file:///C:/Users/user/Downloads/arabic%20questionnaire%20last%201.pdf

Official Title
-----------------
Pregnancy-related VTE; Quality of Patients' Lives

Conditions
-----------------
Health, Subjective

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnancy related event confirmed diagnosis by an objective diagnostic tool (Duplex ultrasonography, CT pulmonary angiography, spiral CT scan or ventilation perfusion scan) consent (acceptance) to participate was obtained alive patients Exclusion Criteria: death an objective diagnostic tool could not be found to confirm the diagnosis their event was not related to pregnancy refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| leg pain | limited mobility (difficulty walking, climbing stairs, bending, kneeling, squatting) | 6 months | 
| Breathlessness | daily activities at work, home or social activities | 6 months | 
| difficulties completing duties at work | Cut down the amount of time you spent on work or other activities , Accomplished less than you would like | 6 months |
KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease) is a nation-wide, ten-year longitudinal cohort study, launched in 2011. The aim of the study is to assess the characteristics and risk factors of progression and complications of CKD of Korea. Pediatric sub-cohort of KNOW-CKD is planned to enroll 450 children with CKD, stage I to V (pre-dialysis).

Detailed Description
-----------------
Seven major pediatric nephrology centers of Korea enrolled children younger than 20 years who had CKD. Medical history taking, questionaire assessment of socio-economic status, anthropometric measurement, and clinical assessment using laboratory and imaging tests were done. Outcome is development of LV hypertrophy or hypertension, growth, neuropsychological status, behavioral status, kidney growth, and quality of life.

Official Title
-----------------
KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease : A 10-year Longitudinal Cohort Study of the Chronic Kidney Disease

Conditions
-----------------
Chronic Kidney Disease(CKD)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: < 20 yr CKD stage 1 through 5 of KDIGO guideline predialysis Exclusion Criteria: - Dialysis

Ages Eligible for Study
-----------------
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children and adolescent<br>children and adolescent CKD patients of any etiology | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| eGFR | eGFR in mL/min/1.73 m2 | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of cardiovascular disease | Hypertrophy in g/m2 | 10 years | 
| Metabolic bone disease | Bone Dexametry in z score | 10 years | 
| Anemia | Anemia in g/dL | 10 years | 
| Growth | Height in z score | 10 years | 
| Health-related quality of life (HRQOL) | PedsQL 4.0 Generic Core Scale Module (Mapi Research Trust, on behalf of Dr James W. Varni, copyright owner of PedsQL™) | 10 years | 
| Cognitive skills and emotional development | K-WAIS score | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic kidney disease(CKD)
Copeptin in Differentiation of Polyuria and Polydipsia

Study Overview
=================
Brief Summary
-----------------
The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy. Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities. The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably. C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure. Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.

Conditions
-----------------
Polyuria, Polydipsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with polydipsia/ polyuria, with indication for performing a deprivation test > 18 years Exclusion Criteria: dDAVP during the last 14d pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary Polydip, D. insipidus<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes insipidus, primary polydipsia, copeptin, Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test
Apomorphine Effects on Experimental Pain

Study Overview
=================
Brief Summary
-----------------
The aims of this study were to assess the effects of the dopamine agonist apomorphine on experimental pain models in healthy subjects and to explore the possible association between these effects and a common polymorphism within the dopamine transporter gene.

Detailed Description
-----------------
Healthy volunteers (n=105) participated in this randomized double-blind, placebo-controlled, cross-over trial. Heat pain threshold and intensity, cold pain threshold, and the response to tonic cold pain (latency, intensity, and tolerance) were evaluated before and for up to 120 min after the administration of 1.5 mg apomorphine/placebo. A polymorphism (DAT-1) within the dopamine transporter gene (SLC6A3) was investigated.

Official Title
-----------------
Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Apomorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - healthy and free from chronic pain of any type did not use any medications other than oral contraceptives were able to understand the purpose and instructions of the study. Exclusion Criteria: - any type of medical or painful condition use of medications or recreational drugs pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Saline<br>Assessment of experimental pain models before and after treatment | Drug: Apomorphine<br>* 1.5 mg Apomorphine<br>* Other names: Active Comparator: Apomorphine;|
| Active Comparator: Apomorphine<br>Assessment of experimental pain models before and after treatment | Drug: Apomorphine<br>* 1.5 mg Apomorphine<br>* Other names: Active Comparator: Apomorphine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cold pain tolerance |  | 120 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
apomorphine, dopamine transporter gene, SLC6A3, cold pressor test, tolerance, experimental pain, dopamine agonist
Gardasil Knowledge

Study Overview
=================
Brief Summary
-----------------
Human papillomavirus (HPV) is the most common viral genital tract infection. The majority of women and men who are sexually active will be exposed to a strain or strains of the virus. While there are hundreds of viral strains, high risk strains are associated cervical and oral cancers. According to the Centers for Disease Control (CDC), between 2008 and 2012 there were 38,793 deaths attributed to HPV related cancers. Vaccinations were created in an attempt to prevent infection from the most common high risks strains of HPV. Gardasil/HPV-9 was created to help prevent HPV related cancers and warts. The HPV-9 vaccine includes protection from 7 strains of HPV associated with 74% of HPV related cancers. While Gardasil was approved and released in 2006, many men and women have not been vaccinated. A national immunization survey in 2011 of teens 13-17 years old noted that only 60% of girls and 40% of boys have received at least one vaccination in the series. While complete vaccination series is recommended, a recent study found that a single dose of Gardasil when compared to placebo created a higher level of serum antibodies in uninfected females.

Detailed Description
-----------------
All patients seen at a single clinic will be offered participation in the anonymous survey. The survey will ask a series of questions regarding basic demographics, sexual history, smoking status, and Gardasil vaccine knowledge. The survey will serve as evidence of the vaccine utility by highlighting patient risk factors for HPV and patient knowledge about the vaccine series.

Official Title
-----------------
Gardasil Anonymous Survey

Conditions
-----------------
HPV

Intervention / Treatment
-----------------
* Other: Gardasil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients 18-26 will be offered participation Exclusion Criteria: Not meeting the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 26 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Gardasil|None-data gathering only|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knowledge about HPV risk factors | The survey asks about Gardasil vaccine knowledge | 1 year |
Quality of Life Among Survivors of Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect information on the long-term side effects of treatment for Hodgkin Lymphoma. We hope to study about 500-800 survivors of Hodgkin Lymphoma. We plan to use the findings from this study to better understand Hodgkin Lymphoma survivors' health and quality of life.

Official Title
-----------------
A Global Assessment of Medical Morbidities and Quality of Life Among Survivors of Hodgkin Lymphoma

Conditions
-----------------
Hodgkin's Disease

Intervention / Treatment
-----------------
* Behavioral: Quality of Life Questionaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy-proven HL Participation in IRB-approved protocols for the first-line treatment of HL between 1975-2000 (IRB #75-104, #75-103, #79-17, #81-103, #90-44, #91-69). English speaking Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Hodgkin lymphoma Survivors | Behavioral: Quality of Life Questionaires<br>* A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the prevalence of late medical complications among HL survivors |  | conclusion of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To study the effect of HL and its treatment on QOL among HL survivors. |  | conclusion of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Survivors, Quality of Life
Cliavist in Infectious and Degenerative Diseases of the Spine

Study Overview
=================
Brief Summary
-----------------
USPIO contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17FDG-PET studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. The aim of this work is to compare the enhancement induced by CLIAVIST in both diseases. The absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.

Official Title
-----------------
Comparison of Cliavist Enhancement in Infectious and Degenerative Diseases of the Spine

Conditions
-----------------
Spine Infection

Intervention / Treatment
-----------------
* Drug: Cliavist


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: spine infection or spine degenerative disease patient agreement obtained Exclusion Criteria: pregnancy MRI contra-indications cliavist contra-indication dextran allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cliavist<br> | Drug: Cliavist<br>* Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| First MRI: performed immediately after gadolinium administration |  | immediately after gadolinium administration | 
| Second MRI: performed 24 hours after cliavist administration |  | 24 hours after cliavist administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, CLIAVIST, MACROPHAGE, INFECTION, SPINE
Effect of Hibiscus Tea and Green Tea Supplements on Athletic Performance, Blood Pressure, Muscle Damage Indices and Oxidative Stress

Study Overview
=================
Brief Summary
-----------------
This study evaluated effect of Hibiscus tea and green tea supplements on athletic performance, blood pressure, muscle damage indices and oxidative stress in male athletes 18-35 years old and cardiovascular disease prevention approach.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: Hibiscus tea
* Dietary Supplement: green tea
* Dietary Supplement: placebo (dextrose)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 to 35 y/o no history of smoking or alcohol consumption no taking nutritional sport supplements during the last 2 months Exclusion Criteria: any injury during intervention any inflammatory disease during the intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hibiscus tea<br>420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day | Dietary Supplement: Hibiscus tea<br> <br> Dietary Supplement: placebo (dextrose)<br> <br> |
| Experimental: green tea<br>450 mg green tea 2 hour after dinner with 1 glass of cool water every day | Dietary Supplement: green tea<br> <br> Dietary Supplement: placebo (dextrose)<br> <br> |
| Placebo Comparator: control group<br>450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day | Dietary Supplement: Hibiscus tea<br> <br> Dietary Supplement: green tea<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| athletic performance assess by heart rate in step test (Harvard test). |  | 6 weeks | 
| blood pressure |  | 6 weeks | 
| serum's malondialdehyde | it will asses by spectrophotometry. | 6 weeks | 
| serum's lactate dehydrogenase | it will asses by calorimetry. | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy male athletes, 18-35 years old
Resynchronization of Left Ventricular Contraction After Reimplantation of Anomalous Left Coronary Artery

Study Overview
=================
Brief Summary
-----------------
Spontaneous resynchronization of dyskinetic segments of the left ventricle occurs after coronary bypass surgery in adults and has been shown in some children. It is, however, unknown what degree of dyskinesis is likely to be reversible in infants with ischemia from anomalous coronary arteries and what criteria would indicate that a resynchronization strategy of biventricular pacing might be needed. These questions need data from quantitative serial tissue Doppler observations of patients from pre-operative to late post-operative follow-up.

Detailed Description
-----------------
We have previously studied, at Children's Healthcare of Atlanta, Egleston Hospital, 2 patients with ALCAPA and one other patient is currently enrolled in a prospective study after recent surgery, also at Children's Healthcare of Atlanta. We propose to study these 3 patients with this rare defect concurrently with their routine echocardiographic evaluations. Data will then be taken off-line for analysis. Standard deviations of times to peak contraction velocity will be assessed for twelve cardiac segments. These will be reevaluated at follow up intervals after surgery on previously obtained echocardiograms. Those subjects in whom improvement of cardiac function, Left Ventricular Ejection Fraction (LVEF) and mitral regurgitation is seen will be compared to those in whom no improvement occurs.

Official Title
-----------------
Resynchronization of Left Ventricular Contraction After Re-implantation of Anomalous Left Coronary Artery From the Pulmonary Artery (ALCAPA) Evaluated by Tissue Doppler Imaging

Conditions
-----------------
Congenital Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Re-implantation of an anomalous left coronary artery from the pulmonary artery Exclusion Criteria: those patients who do not meet inclusion criteria

Ages Eligible for Study
-----------------
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric, cardiac, ALCAPA, Tissue Doppler Imaging